Full text is available at the source.
Abstract
The mRNA-1283 vaccine was first used during the 2025-2026 respiratory virus season.
- This vaccine targets key spike regions of the virus, which are important for immune response.
- Older adults are at higher risk for severe outcomes related to COVID-19.
- Data on vaccine effectiveness can help shape future seasonal vaccination strategies.
Simplified